Filings based on two Phase 3 trials demonstrating significant clinical remission versus placebo and safety profile consistent with previous studies NEW YORK–(BUSINESS WIRE) December 21, 2022 — Pfizer Inc. (NYSE: PFE) announced today that the…Original Article
Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
